Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the Mid-Bore Venous Vascular Closure System (VASCADE® MVP) following multi-access cardiac ablation procedures.
Amin Al-AhmadSuneet MittalDavid DeLurgioG Joseph GallinghouseRodney P HortonMark W PremingerJ David BurkhardtAndrea NatalePublished in: Journal of cardiovascular electrophysiology (2020)
The VVCS was effective for achieving hemostasis following catheter-based procedures; access site closure-related complications and adverse events were well managed.